Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Clinical and Laboratory Characterization of Acquired Von Willebrand Syndrome.

American journal of hematology·2026
Same author

Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phase.

Leukemia research·2026
Same author

Frontline Nilotinib Versus Dasatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Propensity Score Analysis Based on Agenzia Italiana del Farmaco Monitoring Registries.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in Italy.

Haematologica·2026
Same author

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Cancer·2026
Same author

Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Blood·2026

相关实验视频

Updated: Jun 15, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K

骨髓纤维化中的预后和预测模型

Barbara Mora1, Cristina Bucelli1, Daniele Cattaneo1,2

  • 1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35 - 20122, Milan, Italy.

Current hematologic malignancy reports
|August 23, 2024
PubMed
概括

预后模型改善了髓纤维化 (MF) 患者的生存预测. 应用这些模型有助于治疗规划,并加强对MF的个性化护理,改善整体存活率 (OS).

关键词:
移植的全原干细胞移植.雅克抑制剂的使用骨髓纤维化 骨髓纤维化下一代测序测序是什么预测 预后 预测 预测

更多相关视频

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.6K

相关实验视频

Last Updated: Jun 15, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.6K

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 医学统计 医学统计

背景情况:

  • 骨髓纤维化 (MF) 包括前纤维原发性MF (前PMF),明显PMF和二次MF (SMF).
  • 在MF亚型中,总生存率 (OS) 显著不同,PMF前,公开PMF和SMF的中位数OS分别为14,7和9年.
  • 在MF中,死亡率主要是由非克隆性进展和转化到爆发期所驱动的.

研究的目的:

  • 审查生物架构对MF的OS的影响.
  • 突出MF的综合分数和预后模型的开发和应用.
  • 强调OS作为临床试验终点和个性化MF治疗的重要性.

主要方法:

  • 综述最近关于生物架构的发现及其对MF的OS的影响.
  • 评估综合得分和预后模型,以预测PMF和SMF的存活率.
  • 对多变量预测算法的评估,用于MF的治疗决策.

主要成果:

  • 综合得分现在预测了初级MF (PMF) 的生存率.
  • 推使用MYSEC-PM (MYelofibrosis SECondary-prognostic model) 模型来对小的OS进行估计.
  • 多变量预测算法可以支持MF患者的关键治疗决策.
  • 累积数据澄清了SMF中的分子景观的预后作用.

结论:

  • 预测模型对于OS预测和MF治疗规划至关重要.
  • 及时应用预后模型对于个性化的MF患者护理方法至关重要.
  • 在MF的临床试验中,OS应被视为一个相关的终点.